B. Braun Medical, a smart infusion therapy and pain management company, has received the US Food and Drug Administration (FDA) 510(k) clearance for the Introcan Safety 2 Deep Access IV Catheter.
The offering is the latest addition to the Introcan Safety 2 IV Catheter range.
The Introcan Safety 2 Deep Access IV Catheter combines features from the original Introcan Safety 2 Multi-Access and Introcan Safety Deep Access Catheters.
It offers fully automatic needlestick protection and multi-access blood control in longer lengths.
The catheter is designed for patients with challenging vascular access to provide deeper vein access and longer dwell times.
According to B. Braun Medical, this catheter increases peripheral intravenous catheter (PIVC) dwell times to about 5.7 days, compared to 3.8 days for standard long PIVCs in trials.
In addition, it can reduce the need for PIVC restarts and the use of costly invasive devices like peripherally inserted central catheters (PICC).
Furthermore, the multi-access blood control hub in the latest PIVC minimises blood exposure. It also eliminates the need for vessel occlusion during insertion and access and lowers the need for blood cleanup throughout IV therapy.
B. Braun Medical IV systems and securement vascular access marketing director Chad Laity said: “We are excited to broaden our Introcan Safety 2 IV Catheter portfolio, allowing our customers to benefit from passive safety and blood exposure protection with deep access technology.
“By offering a reliable solution for challenging cases, we aim to help improve patient outcomes and reduce the need for more complex procedures.”
The launch of the Introcan Safety 2 Deep Access IV Catheter supports B. Braun Medical’s Peripheral Advantage Program. This programme aims to optimise clinical skills and enhance product performance.
It focuses on improving clinical outcomes and elevating the patient experience with peripheral IV care in hospitals.
Headquartered in Pennsylvania, B. Braun Medical is part of the B. Braun Group of Companies in the US. The group also includes B. Braun Interventional Systems, Aesculap, and CAPS.
The company has around 8,500 employees in more than 30 locations in North America.
In June, B.Braun Interventional Systems (BIS) introduced its ACCEL All-Purpose and Biliary Drainage Catheters. These catheters feature TrueGlide Hydrophilic Coating, designed for percutaneous drainage.
